Beximco has seen double-digit domestic growth as the company launched 22 new products and built on its recent Sanofi Bangladesh deal. Meanwhile, internationally the Bangladesh-based company has entered eight new markets.
Bangladesh’s Beximco Pharma has reported a 15.4% growth in domestic sales to BDT26.4bn ($307.9m) for its financial year ended 30 June 2021, on the back of its recent acquisition of a majority stake in Sanofi Bangladesh and 22 new domestic launches.
Commenting on the results, Nazmul Hassan, managing director of Beximco, said that “against the backdrop of logistical and operational challenges...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
